ãã€ãªãã¯ãããžãŒäŒæ¥ã§ãã Enanta Pharmaceuticals, Inc. ã¯ããŠã€ã«ã¹ææçãèèçŸæ£ã®æ²»çã®ããã®äœååå»è¬åã®çºèŠãšéçºãè¡ã£ãŠããŸããç ç©¶éçºã®å¯Ÿè±¡ãšãªãçŸæ£ã«ã¯ãRS ãŠã€ã«ã¹ãSARS-CoV-2ãããã¡ã¿ãã¥ãŒã¢ãŠã€ã«ã¹ãB åèçãŠã€ã«ã¹ãªã©ããããŸããå瀟ã¯ãæ
¢æ§ C åèçãŠã€ã«ã¹ã®æ²»çè¬ã§ããããªã¿ãã¬ãã«ãã°ã¬ã«ãã¬ãã«ãªã©ãHCV NS3 ããã³ NS3/4A ãããã¢ãŒãŒé»å®³ååç©ãç¹å®ãéçºãåååããããã«ãAbbott Laboratories ãšå
±åéçºããã³ã©ã€ã»ã³ã¹å¥çŽãçµãã§ããŸããEnanta Pharmaceuticals, Inc. 㯠1995 幎ã«èšç«ãããããµãã¥ãŒã»ããå·ãŠã©ãŒã¿ãŒã¿ãŠã³ã«æ¬ç€Ÿã眮ããŠããŸãã